---
title: "HYBIO: Acetate Degarelix raw material drug has been approved for listing"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/246060803.md"
description: "According to the Zhitong Finance APP, HYBIO announced that its wholly-owned subsidiary HYBIO (Wuhan) Co., Ltd. (referred to as \"HYBIO Wuhan\") has received the \"Approval Notice for the Listing Application of Chemical Raw Materials\" issued by the National Medical Products Administration for the raw material drug Degarelix. Degarelix is a gonadotropin-releasing hormone (GnRH) receptor antagonist that reversibly binds to pituitary GnRH receptors, thereby reducing the release of gonadotropins and testosterone, and can be used for the treatment of patients with advanced prostate cancer"
datetime: "2025-06-25T10:29:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/246060803.md)
  - [en](https://longbridge.com/en/news/246060803.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/246060803.md)
generator: "portal-rs"
---

# HYBIO: Acetate Degarelix raw material drug has been approved for listing

According to the Zhitong Finance APP, HYBIO (300199.SZ) announced that its wholly-owned subsidiary HYBIO (Wuhan) Co., Ltd. (referred to as "HYBIO Wuhan") has received the "Approval Notice for the Listing Application of Chemical Raw Materials" issued by the National Medical Products Administration for the raw material drug Degarelix. Degarelix is a gonadotropin-releasing hormone (GnRH) receptor antagonist that reversibly binds to pituitary GnRH receptors, thereby reducing the release of gonadotropins and testosterone, and can be used for the treatment of patients with advanced prostate cancer

### Related Stocks

- [300199.CN](https://longbridge.com/en/quote/300199.CN.md)

## Related News & Research

- [Subscribe for Symbiotec Pharmalab Ltd IPO; Ajcon Global](https://longbridge.com/en/news/296742246.md)
- [Haisco Enters Into Exclusive License Agreement With New US Venture Founded By Population Health Partners And ARCH Venture Partners](https://longbridge.com/en/news/296910145.md)
- [Livzon Pharma buys 3.5% Xinbeijiang Pharma stake for RMB 106.7 million](https://longbridge.com/en/news/296601614.md)
- [FFM: Green Bay Copper-Gold Project delivers strong economics, resource growth, and secured funding](https://longbridge.com/en/news/296841684.md)
- [Four Nines Gold reports hydrothermal breccia hits in first three Hayden Hill drill holes, assays pending](https://longbridge.com/en/news/296918643.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**